Healthcare Professional Portal

Click here for prescribing information and adverse event reporting information (hosted externally).
Our Services
PI & AE

Introduction to QUVIVIQ™ ▼ (daridorexant)

QUVIVIQ™ video overview

Watch our short 3-minute video of Product Specialist, Naressa Govender-Petrikaitis, giving an introduction to QUVIVIQ™. Here she explains the following topics:

  1. Mechanism of action
    Unlike other hypnotics, QUVIVIQ™ targets and blocks a neurotransmitter that is a possible cause of overactive wake signalling1,2
  2. Efficacy and safety
    The efficacy and safety of QUVIVIQ™ including clinical trial results and its side effect profile
  3. QUVIVIQ™ administration
    Dosage and ongoing management information for optimal patient outcomes

Promotional material from Idorsia Pharmaceuticals UK Ltd.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

References

  1. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
  2. Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
  3. NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.
  4. Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00793
| Date of preparation: July 2025
Copyright © 2026 Idorsia Pharmaceuticals Ltd

Related posts

Symposia Replay Hub

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Beyond sleepless nights: managing chronic insomnia in adults in primary care

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Self-led e-learning programme: Understanding chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Mechanism of action of QUVIVIQ™▼ (daridorexant)

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Mechanism of chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Treatment algorithm for adults with chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Vodcast series: Insomnia Uncovered

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Overactive wake signalling as a possible cause of chronic insomnia

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Insomnia conversation starter

Patient support material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Plain language summary of QUVIVIQ™▼ (daridorexant) phase 3 clinical trials

Promotional material from Idorsia Pharmaceuticals UK Ltd.

  • Learn more

Other readers liked

...Less than 1 hour

Symposia Replay Hub

Replay Video
Access recordings from Idorsia-sponsored symposia featuring healthcare professionals discussing clinical data and practical considerations for QUVIVIQ™▼ (daridorexant) in chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01145
| Date of preparation: November 2025
...Less than 1 hour

Beyond sleepless nights: managing chronic insomnia in adults in primary care

Replay CPD hours Video
Catch up on our CPD-accredited webinar series in collaboration with MIMS Learning. Our expert speakers explore the impact of chronic insomnia in diverse patient populations, discuss diagnostic approaches and share real-life experiences with patients.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-01116
| Date of preparation: October 2025
  • New resource
...Less than 1 hour

Self-led e-learning programme: Understanding chronic insomnia

E-learning course
This series of 6 20-minute modules has been reviewed by an expert faculty in sleep and insomnia, to support you in learning about chronic insomnia and the treatment options available for your patients.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00740
| Date of preparation: April 2025
  • Popular resource
...Less than 5 min.

Mechanism of action of QUVIVIQ™▼ (daridorexant)

Video
Watch to discover the mechanism of action of QUVIVIQ™, and how it can reduce overactive wake signalling in patients with chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00789
| Date of preparation: July 2025
...Less than 5 min.

Mechanism of chronic insomnia

Video
Watch to discover the role of overactive wake signalling as a possible cause of chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00790
| Date of preparation: July 2025
...Less than 5 min.

Treatment algorithm for adults with chronic insomnia

Downloadable document
Developed by Idorsia Pharmaceuticals Ltd, in consultation with the authors, utilising the BMC Primary Care publication “Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians” Selsick et al. BMC Primary Care (2024) 25:138

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00792
| Date of preparation: July 2025
...Less than 15 min.

Vodcast series: Insomnia Uncovered

Vodcast Video
Join Dr Allie Hare, consultant in sleep medicine in London, and Dr Cameron Livingston, a GP specialising in sleep in Glasgow, over a series of 6 vodcasts, as they discuss insomnia, its impact, diagnosis and treatment.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00788
| Date of preparation: July 2025
  • Popular resource
...Less than 5 min.

Overactive wake signalling as a possible cause of chronic insomnia

Video
Watch this short presentation by Professor Dr. med. G. Hajak as he provides a concise introduction to the role of overactive wake signalling as a possible cause for chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00786
| Date of preparation: July 2025
...Less than 5 min.

Insomnia conversation starter

Downloadable document
This interactive questionnaire is designed to support your consultation with patients, helping to identify patients’ sleep concerns.

Patient support material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00785
| Date of preparation: July 2025
...Less than 15 min.

Plain language summary of QUVIVIQ™▼ (daridorexant) phase 3 clinical trials

Downloadable document
Access a summary of the Lancet-published paper by Emmanuel Mignot et al. and learn about the impact of QUVIVIQ™ on night-time and daytime symptoms in patients with chronic insomnia.

Promotional material from Idorsia Pharmaceuticals UK Ltd.

UK-DA-00787
| Date of preparation: July 2025

Gain access to resources on chronic insomnia

Subscribe to get priority updates  and access to videos, data and patient resources, plus details about us and our offerings.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Discover how QUVIVIQ™ ▼ (daridorexant) is different to other hypnotics1,2:

Works differently1,2

Is taken differently1,3

Is experienced differently1,4

Learn more
Learn more

Book an appointment

One of our product specialists would be happy to answer your questions.

References

1 – QUVIVIQ™ Idorsia Pharmaceuticals LTD, summary of product characteristics. Last updated: September 2024. 2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708. 3 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139. 4 –. Robbins R, et al. Front Sleep. 2022; 1: 935228. 5 – Di Marco T, et al. CNS Drugs. 2023; 37(7): 639–653. 6 – Kunz D, et al. CNS Drugs. 2022; 37(1): 93–106.

 

UK-DA-XXXXX | Date of preparation: February 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd

Welcome to the Idorsia UK
Healthcare Professional portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

I am a UK healthcare professional
I am a member of the public

UK-DA-00217 | Date of preparation: October 2023

Copyright © 2023 Idorsia Pharmaceuticals Ltd

Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Sign up

You are now leaving pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

Continue to medicines.org.uk

UK-DA-00439 | Date of preparation: May 2024

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Gain access to resources on chronic insomnia

Fill in the form below to get instant access to this resource and unlock our full library of downloadable materials.

You are now leaving pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
Cancel
Go to link

UK-DA-00445 | Date of preparation: May 2024

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on chronic insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings